Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1215-1221

  Tsurusawa, Masahito ^a   Mori, Tetsuya ^b   Kikuchi, Akira ^c   Mitsui, Tetsuo ^d   Sunami, Shosuke ^e   Kobayashi, Ryoji ^f   Takimoto, Tetsuya ^b   Saito, Akiko ^g   Watanabe, Tomoyuki ^h   Fujimoto, Junichiro ^b   Nakazawa, Atsuko ^b   Ohshima, Kouichi ⁱ   Horibe, Keizo ^g  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^e NARITA RED CROSS HOSPITAL   (Japan)

^f SAPPORO HOKUYU HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h AICHI GAKUIN UNIVERSITY   (Japan)

ⁱ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B NHL03; Childhood; JPLSG; Non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE TOXICITY; ADOLESCENT; ANEMIA; ARTICLE; ASCITES; B CELL LYMPHOMA; BONE MARROW; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD CANCER; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFANT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSATILE DRUG RELEASE; RENAL REPLACEMENT THERAPY; SECOND CANCER; SEPSIS; STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

B-NHL03; CHILDHOOD; JPLSG; NON-HODGKIN LYMPHOMA;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; LYMPHOMA, B-CELL; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84899669086     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24975     Document Type: Article

References (29)

1. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage. A report of the Berlin Frankfurt-Münster Group. J Clin Oncol 1995; 13:359-372.
2. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: Reports of the Berlin-Frankfurt-Münster Group trial NHL-BFM 90. Blood 1999; 94:3294-3306.
3. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97:3370-3379.
4. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents. It is possible to reduce treatment for the early responding patients. Blood 2007; 109:2773-2780.
5. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109:2736-2743.
6. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: Results of the FAB/LMB 96 international study. Br J Haematol 2008; 141:840-847.
7. Shimizu H, Kikuchi M, Takaue Y, et al. Improved treatment results of non-Hodgkin's lymphoma in children: A report from the Children's Cancer and Leukemia Study Group of Japan. Int J Hematol 1995; 61:85-96.
8. Horibe K, Akiyama Y, Kobayashi M, et al. Treatment outcome of AT-B88 regimen for B-cell non-Hodgkin's lymphoma and surface immunoglobulin-positive acute lymphoblastic leukemia in children. Int J Hematol 1997; 66:89-98.
9. Tsurusawa M, Taga T, Horikoshi Y, et al. Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: A report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group. Leuk Lymphoma 2008; 49:734-739.
10. Kikuchi A, Mori T, Fujimoto J, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. Leuk Lymphoma 2008; 49:757-762.
11. Lee SH, Yoo KH, Sung KW, et al. Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype? Pediatr Blood Cancer 2013; 60:1842-1847.
12. Jaffe ES, Harris NL, Stein H, et al., editors. WHO classification of tumors, pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
13. Murphy SB. Classification, staging and results of treatment of childhood NHL, dissimilarities from lymphoma in adults. Seminars in Oncology 1980; 7:332-339.
14. Horibe K, Saito AM, Takimoto T, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): Based on registry data from the Japanese Society of Pediatric Hematology. Int J hematol 2013; 98:74-88.
15. Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 2008; 142:329-347.
16. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 2008; 112:1374-1381.
17. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003; 97:1991-1998.
18. Davies SM. Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. Pediatric Blood Cancer 2007; 48:727-730.
19. Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 1979; 32:1082-1084.
20. Takagi T, Sakai C, Oguro M. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkins lymphoma. Oncology 1990; 47:25-28.
21. Niitsu N, Umeda M. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma. Leukemia 1998; 12:1457-1460.
22. Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: Comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 1999; 63:337-344.
23. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: A randomized phase II study. J Cancer Res Clin Oncol 2004; 130:107-113.
24. Zhai L, Guo C, Cao Y, et al. Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: Single center, 15-year experience. Int J Hematol 2010; 91:78-86.
25. Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010; 24:335-344.
26. Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group Study. Pediatr Blood Cancer 2010; 55:1287-1295.
27. Shimomura Y, Baba R, Watanabe A, et al. Japanese Childhood Cancer and Leukemia Study Group (JCCLSG). Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57:461-466.
28. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28:3115-3121.
29. Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report. Br J Haematol 2013; 162:678-683.